A RANDOMIZED PHASE III CLINICAL TRIAL FOR THE ADDITION OF DOCETAXEL TO ANDROGEN
RECEPTOR PATHWAY INHIBITORS IN PATIENTS WITH METASTATIC CASTRATION SENSITIVE
PROSTATE CANCER AND SUBOPTIMAL PSA RESPONSE (TRIPLE-SWITCH)
- Registry ID
- PR.26
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY
- Start date
- 2025-03-27
- Last update
- 2024-12-16
Conditions
- CASTRATION RESISTANT PROSTATE CANCER
Related clinical trials
- A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND
EXPANSION STUDY OF GSK5458514 PSMA TARGETING T CELL ENGAGER ALONE OR IN
COMBINATION WITH OTHER ANTI-CANCER AGENTS IN ADULT PARTICIPANTS WITH METASTATIC
CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)
- A MULTINATIONAL, MULTICENTER, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPENLABEL,
PHASE 3 STUDY OF LUTETIUM (177LU) ROSOPATAMAB TETRAXETAN IN COMBINATION WITH
STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN PATIENTS WITH PROSTATE-SPECIFIC
MEMBRANE ANTIGEN (PSMA) POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE
CANCER (MCRPC) AFTER ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) TREATMENT
- A PHASE 3, TWO-PART, RANDOMIZED, OPEN-LABEL, ADAPTIVE STUDY COMPARING BMS-
986365 VERSUS INVESTIGATOR'S CHOICE OF THERAPY COMPRISING EITHER DOCETAXEL OR
SECOND ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI), IN PARTICIPANTS WITH
METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) - RECHARGE
- SATISFACTION: A PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY OF [225AC]AC-PSMA-R2 IN MEN WITH HEAVILY PRE-TREATED PSMA POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH OR WITHOUT PRIOR 177LU-LABELLED PSMA-TARGETED RADIOLIGAND THERAPY
- OPTION-DDR: A RANDOMIZED PHASE III TRIAL INVESTIGATING PLATINUM AND TAXANE CHEMOTHERAPY IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH ALTERATIONS IN DNA DAMAGE RESPONSE (DDR) GENES
- [(A)C-225]-PSMA-62 PHASE I/II (C)LINICAL TRIAL TO (CHARACTERIZE (E)FFICACY, SAFETY, TO(L)ERABILITY, AND DOSIMETRY IN BIOCHEMICALLY RECURRENT AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER (ACCEL)
View on source registry